Founded in 2018, Xellera Therapeutics operates Hong Kong’s first commercial cGMP facility for cell and gene therapies. Offering comprehensive CDMO solutions—process development, GMP manufacturing, testing, and cryostorage—our services meet US FDA, EMA, and PIC/S standards to accelerate ATMP development across Asia. https://www.xelleratherapeutics.com/